Anne-Marie Koop

218 12. Paulin R, Sutendra G, Gurtu V, Dromparis P, Haromy A, Provencher S, Bonnet S, Michelakis ED. A miR-208-Mef2 axis drives the decompensation of right ventricular function in pulmonary hypertension. Circ R es 2015;116:56–69. 13. Sutendra G, Dromparis P, Paulin R, Zervopoulos S, Haromy A, Nagendran J, Michelakis ED. A metabolic remodeling in right ventricular hypertrophy is associated with decreased angiogenesis and a transition from a compensated to a decompensated state in pulmonary hypertension. J Mol Med E.D. Michelakis, Department of Medicine, University of Alberta, Edmonton, AB T6G 2B7, Canada; 2013;91:1315–1327. 14. Balestra GM, Mik EG, Eerbeek O, Specht PAC, Laarse WJ van der, Zuurbier CJ. Increased in vivo mitochondrial oxygenation with right ventricular failure induced by pulmonary arterial hypertension: Mitochondrial inhibition as driver of cardiac failure? Respir Res C.J. Zuurbier, Department of Anesthesiology, Laboratory of Experimental Intensive Care and Anesthesiology, AMC, Amsterdam, Netherlands; 2015;16. 15. Piao L, Fang YH, Cadete VJJ, Wietholt C, Urboniene D, Toth PT, Marsboom G, Zhang HJ, Haber I, Rehman J, Lopaschuk GD, Archer SL. The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: Resuscitating the hibernating right ventricle. J Mol Med 2010;88:47–60. 16. Piao L, Sidhu VK, Fang Y-H, Ryan JJ, Parikh KS, Hong Z, Toth PT, Morrow E, Kutty S, Lopaschuk GD, Archer SL. FOXO1-mediated upregulation of pyruvate dehydrogenase kinase-4 (PDK4) decreases glucose oxidation and impairs right ventricular function in pulmonary hypertension: therapeutic benefits of dichloroacetate. J Mol Med S.L. Archer, Department of Medicine, Queen’s University Kingston, Kingston, K7L 3N6, ON, Canada; 2013;91:333–346. 17. Feen DE Van Der, Weij M, Smit-Van Oosten A, Jorna LM, Hagdorn QAJ, Bartelds B, Berger RMF. Shunt surgery, right heart catheterization, and vascular morphometry in a rat model for flow-induced pulmonary arterial hypertension. J Vis Exp 2017;2017:1–11. 18. Sheikh AM, Barrett C, Villamizar N, Alzate O, Valente AM, Herlong JR, Craig D, Lodge A, Lawson J, Milano C, Jaggers J. Right ventricular hypertrophy with early dysfunction: A proteomics study in a neonatal model. J Thorac Cardiovasc Surg A.M. Sheikh, Department of Pediatric Cardiac Surgery, the Neuroproteomics Center, Durham, NC, United States; 2009;137:1146–1153. 19. Olivetti G, Ricci R, Lagrasta C, Maniga E, Sonnenblick EH, Anversa P. Cellular basis of wall remodeling in long-term pressure overload-induced right ventricular hypertrophy in rats. Circ Res Department of Pathology, University of Parma, 43100 Parma; 1988; 63 :648–657. 20. Lauva IK, Brody E, Tiger E, Kent RL, Copper G 4th, Marino TA. Control of myocardial tissue components and cardiocyte organelles in pressure-overload hypertrophy of the cat right ventricle. Am J Anat United States; 1986;177:71–80. 21. Fang Y-H, Piao L, Hong Z, Toth PT, Marsboom G, Bache-Wiig P, Rehman J, Archer SL. Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: Exploiting Randle’s cycle. J Mol Med S.L. Archer, Medicine/Cardiology, University of Chicago, Chicago, IL 60637, United States; 2012;90:31–43. 22. Piao L, Fang Y-H, Parikh K, Ryan JJ, Toth PT, Archer SL. Cardiac glutaminolysis: A maladaptive cancer metabolism pathway in the right ventricle in pulmonary hypertension. J Mol Med S.L. Archer, Department of Medicine, Queen’s University, Etherington Hall,